Wave expands team with new appointments
March 1, 2016Medical Communications
Medical education specialist, Wave, has made five new appointments, which the company says reflects the growth in its business over …
Exelixis signs $200 million licensing deal for cancer drug
March 1, 2016Research and Development, Sales and Marketing Cancer, Cometriq, Exelixis, ipsen
Exelixis has signed a licensing agreement with French biotech firm Ipsen for its cancer drug Cometriq (cabozantinib) for an upfront …
Two Celgene cancer drugs approved in Ireland
March 1, 2016Research and Development, Sales and Marketing Abraxane, Cancer, Celgene, Revlimid, imnovid
Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory …
Delivering successful new drugs
March 1, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, patents, pharma
Pharma companies are struggling with challenges specific to their industry. Patents for many drugs, that had created massive amounts of …
The future for pharma packaging
March 1, 2016Manufacturing and Production distribution, packaging, research, supply chain
The pharmaceutical packaging market is projected for strong growth through 2020, driven by innovation for new products and materials and …
Lupin to set up manufacturing plant in Japan
March 1, 2016Manufacturing and Production Japan, Lupin, manufacturing
Indian drugmaker Lupin is, via its Japanese unit Kyowa, setting up a manufacturing unit in Japan as part of its …
South Florida Uni begins £875,000 dementia drug research programme
March 1, 2016Manufacturing and Production, Research and Development Alzheimer's
Funding from a consortium worth £875,000 pounds has helped kick start a new dementia drug research program at the University …
Japan approves Astellas hyperphosphatemia drug
March 1, 2016Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Hyperphosphatemia, Japan, Kiklin
Astellas Pharma has received approval from the Ministry of Health, Labour and Welfare in Japan for a supplemental new drug …
Valeant shares slide on SEC investigation announcement
March 1, 2016Manufacturing and Production, Research and Development, Sales and Marketing Philidore, Valeant, regulation
Shares at troubled Valeant plummeted some 20% Monday after the company said it was under investigation by the Securities and …
AstraZeneca licenses European rights to constipation drug for $70m
March 1, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, EU, Japan, Luke Miles, ProStrakan Group, constipation drug, moventig
AstraZeneca said on Tuesday it has agreed to licence rights to its constipation drug Moventig to Japan’s ProStrakan Group for …
AstraZeneca announces tremelimumab setback in mesothelioma test
March 1, 2016Manufacturing and Production, Research and Development AstraZeneca, Cancer, MedImmune, tremelimumab
AstraZeneca and its global biologics research and development arm, MedImmune, have announced a setback in the result of their Phase …
GenSight begins Phase III retinal disease trials
February 29, 2016Research and Development GenSight, Leber’s Hereditary Optic Neuropathy, retinal disease
French biotech GenSight has begun enrolling patients for two parallel pivotal Phase III trials with its lead candidate GS010, a …
CHMP recommends Lilly psoriasis drug for approval
February 29, 2016Research and Development Eli Lilly, Taltz, psoriasis
Eli Lilly’s Taltz (ixekizumab) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
Roche finds contradictory results in identical Phase III asthma trials
February 29, 2016Manufacturing and Production, Research and Development Roche, lebrikizumab asthma
Roche has reported contradictory results from two identical Phase III studies of lebrikizumab in severe asthma, with one showing the …
New epilepsy drug launches in UK
February 29, 2016Medical Communications, Research and Development, Sales and Marketing Briviact, UCB Pharma, epilepsy
UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary …
FDA approves Roche’s Gazyva in follicular lymphoma
February 29, 2016Research and Development, Sales and Marketing Levact, MabThera
Strong Phase III results have seen the US FDA approve Roche’s Gazyva (obinutuzumab) plus Levact (bendamustine) chemotherapy followed by Gazyva …
Drug repurposing can help tackle Rare Diseases, says charity
February 29, 2016Medical Communications, Research and Development, Sales and Marketing rare diseases
On Rare Disease Day 2016, UK charity Findacure says existing drugs may hold the key to new treatments and repurposing …
Boehringer launches IPF initiatives
February 29, 2016Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev
Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …
FDA approves new indication for Novartis’ Afinitor
February 29, 2016Research and Development, Sales and Marketing Afinitor, Novartis
Novartis’ cancer drug Afinitor (everolimus) has been granted FDA approval in a new indication: for the treatment of adult patients …
Eisai slams new Cancer Drugs Fund for delaying patient access
February 26, 2016Research and Development, Sales and Marketing Cancer Drugs Fund, Eisai, Lenvima
Eisai has aimed strong criticism at NHS England for its approval of reforms to the Cancer Drugs Fund, calling the …
Latest content
AI: an early warning system for patient safety
Highlighting the value of lab research for healthcare innovation
